What is Dyne Therapeutics, Inc.'s debt issuance proceeds?

Dyne Therapeutics, Inc. (DYN) reported debt issuance proceeds of $49.45M in Q4 2025.

What does debt issuance proceeds mean?

Cash received from issuing bonds, notes, term loans, and other debt instruments in the capital markets or from bank lending.

Dyne Therapeutics, Inc. DYN Debt Issuance Proceeds

Debt Issuance Proceeds at other companies

Arrowhead ResearchARWR

$3.16M—

Scholar RockSRRK

$1K—

CytokineticsCYTK

$182.37M—

ModernaMRNA

$150M—

BioMarin PharmaceuticalsBMRN

——

Other financials

Income statement

See full

Operating income-$125.3M-2.4%

Net income-$120.9M-4.8%

EPS (diluted)-$0.73+30.5%

Balance sheet

See full

Cash & equivalents$753.1M+59.5%

Total debt$168.7M+623%

Total equity$865.1M+29.3%

Total assets$1.1B+49.8%

Cash flow

See full

Operating cash flow-$144.9M-36.9%

CapEx$221.0K-77.5%

Free cash flow-$145.1M-35.8%

Valuation

See full

Market cap$3.35B+153%

Returns & leverage

See full

Return on equity-58.9%-4.4pp

Debt / equity0.2×+0.2×

Current ratio19.9×-0.4×

Where this comes from

Reported directly by Dyne Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceOfLongTermDebt.

The official record: Dyne Therapeutics, Inc.’s 10-K, filed March 2, 2026, on SEC EDGAR. View the filing →

Ask your AI about Dyne Therapeutics, Inc.'s debt issuance proceeds.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Dyne Therapeutics, Inc.'s debt issuance proceeds?: Dyne Therapeutics, Inc. (DYN) reported debt issuance proceeds of $49.45M in Q4 2025.
What does debt issuance proceeds mean?: Cash received from issuing bonds, notes, term loans, and other debt instruments in the capital markets or from bank lending.